Dr. Irum Khan
Claim this profileUniversity of Illinois
Studies Myeloid Leukemia
Studies Acute Myeloid Leukemia
3 reported clinical trials
9 drugs studied
Area of expertise
1Myeloid Leukemia
BCR/ABL negative
BCR/ABL positive
BCR-ABL positive
2Acute Myeloid Leukemia
BCR/ABL negative
BCR/ABL positive
BCR-ABL positive
Affiliated Hospitals
Clinical Trials Irum Khan is currently running
Pembrolizumab + TKI
for Chronic Myeloid Leukemia
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Recruiting1 award Phase 2
Tamibarotene + Azacitidine
for Myelodysplastic Syndrome
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Recruiting1 award Phase 34 criteria
More about Irum Khan
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Irum Khan has experience with
- Tamibarotene
- Azacitidine
- Pembrolizumab
- Dasatinib
- Imatinib Mesylate
- Nilotinib
Breakdown of trials Irum Khan has run
Myeloid Leukemia
Acute Myeloid Leukemia
Myelodysplastic syndrome
Myelodysplastic Syndrome
Klinefelter Syndrome and Triple X Syndrome.
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Irum Khan specialize in?
Irum Khan focuses on Myeloid Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Myeloid Leukemia has involved BCR/ABL negative patients, or patients who are BCR/ABL positive.
Is Irum Khan currently recruiting for clinical trials?
Yes, Irum Khan is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Irum Khan has studied deeply?
Yes, Irum Khan has studied treatments such as Tamibarotene, Azacitidine, Pembrolizumab.
What is the best way to schedule an appointment with Irum Khan?
Apply for one of the trials that Irum Khan is conducting.
What is the office address of Irum Khan?
The office of Irum Khan is located at: University of Illinois, Chicago, Illinois 60612 United States. This is the address for their practice at the University of Illinois.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.